Brief: BioCorRx Inc Says GLP Preclinical Studies Uninterrupted By COVID-19 To Date
22/05/2020 13:51
May 22 (Reuters) - BioCorRx Inc BICX.PK :
* BIOCORRX INC - GLP PRECLINICAL STUDIES OF BICX102 HAVE
BEEN
UNINTERRUPTED BY COVID-19 TO DATE
* BIOCORRX INC - CONTINUE TO ADVANCE PRECLINICAL STUDIES
WITH
VDM-001
Source text for Eikon: ID:nGNX2bYXPG
Further company coverage: BICX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biocorrx
See all newsBrief: BioCorRx Submits Fast Track Application To FDA For Bicx104, An Implantable Biodegradable Naltrexone Pellet For The Treatment Of Opioid Use Disorder
Brief: Biocorrx Announces Completion Of Treatment Phase Of Study Subjects And Preliminary Safety Data From Phase I Clinical Trial Of Bicx104
Brief: BioCorRx Partners With Government Plus To Expand Its Beat Addiction Recovery Program In The United States
Brief: Biocorrx Completes Final Subject Enrollment In Phase I Clinical Trial Of Bicx104, An Implantable Naltrexone Pellet For The Treatment Of Opioid Use Disorder
Brief: BioCorRx Begins Recruitment for Clinical Trial of BICX104